FIELD: medicine, gastroenterology, pharmacy.
SUBSTANCE: invention relates to oral dosed formulation of drugs with the sustained-release effect comprising multiple units and with regulated release of an active substance depending on species and amount of stomach and digestive tract filling. Method involves using the decomposing hydrophilic polymer of hydroxypropylcellulose and limitation of maximal size of polymer particles containing an active substance, i. e. ≤ 3 mm. Invention provides the uniform absorption of an active substance.
EFFECT: improved preparing method.
7 cl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HARD, SUITABLE FOR ORAL INTAKE PHARMACEUTICAL FORMS OF APPLICATION, CONTAINING RIVAROXABAN WITH MODIFIED RELEASE | 2005 |
|
RU2420290C2 |
| GALENIC COMPOSITIONS OF ORGANIC COMPOUNDS | 2017 |
|
RU2773029C2 |
| DEGRADATION-RESISTANT DOSAGE FORM WITH DELAYED RELEASE OF OXYCODONE HYDROCHLORIDE | 2010 |
|
RU2461381C2 |
| EXTENDED RELEASE DURABLE DOSAGE FORMS | 2006 |
|
RU2399371C2 |
| PHARMACEUTICAL COMPOSITION IN FORM OF SINGLE ORAL DOSE CONTAINING LEVODOPA, CARBIDOPA AND ENTACAPONE, OR SALTS THEREOF | 2009 |
|
RU2519159C2 |
| ORAL DOSAGE FORMS OF TOFACITINIB WITH CONTINUOUS RELEASE | 2014 |
|
RU2790166C2 |
| SOLID PHARMACEUTICAL PREPARATIVE FORMULATIONS WITH CONTROLLED RELEASE BASED ON CYCLODEXTRIN SULFOALKYL ESTERS | 2000 |
|
RU2233176C9 |
| FORM OF PROLONGED VENLAFAXINE HYDROCHLORIDE LIBERATION | 2004 |
|
RU2340331C2 |
| TOFACITINIB ORAL SUSTAINED RELEASE DOSAGE FORMS | 2014 |
|
RU2674345C2 |
| PHARMACEUTICAL COMPOSITION DISTINGUISHED BY PROLONGED RELEASE INDEPENDENT OF IONIC FORCE | 2001 |
|
RU2285519C2 |
